AIM ImmunoTech Enters Material Definitive Agreement
Ticker: AIM · Form: 8-K · Filed: Nov 19, 2025 · CIK: 946644
Sentiment: neutral
Topics: material-definitive-agreement, financial-obligation
TL;DR
AIM ImmunoTech just signed a big deal, creating a new financial obligation. Details to follow.
AI Summary
On November 18, 2025, AIM ImmunoTech Inc. entered into a material definitive agreement, creating a direct financial obligation. The company, formerly known as Hemispherx Biopharma Inc., is incorporated in Delaware and headquartered in Ocala, Florida.
Why It Matters
This filing indicates a new financial commitment or obligation for AIM ImmunoTech, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — Entering into new material definitive agreements and financial obligations can introduce financial risks and operational changes for a company.
Key Players & Entities
- AIM ImmunoTech Inc. (company) — Registrant
- Hemispherx Biopharma Inc. (company) — Former company name
- November 18, 2025 (date) — Date of earliest event reported
- 2117 SW Highway 484, Ocala FL 34473 (location) — Principal executive offices address
FAQ
What type of material definitive agreement did AIM ImmunoTech Inc. enter into?
The filing states that AIM ImmunoTech Inc. entered into a material definitive agreement that resulted in the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on November 18, 2025.
What is the principal executive office address for AIM ImmunoTech Inc.?
The principal executive office address for AIM ImmunoTech Inc. is 2117 SW Highway 484, Ocala FL 34473.
What was AIM ImmunoTech Inc. formerly known as?
AIM ImmunoTech Inc. was formerly known as Hemispherx Biopharma Inc.
What is the SIC code for AIM ImmunoTech Inc.?
The Standard Industrial Classification (SIC) code for AIM ImmunoTech Inc. is 2836, which corresponds to Biological Products (no diagnostic substances).
Filing Stats: 1,025 words · 4 min read · ~3 pages · Grade level 12 · Accepted 2025-11-19 07:00:32
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share AIM NYSE American Item
- $3,301,250 — ") with an original principal amount of $3,301,250 in a private placement (the " Private P
- $781,250 — arries an original issuance discount of $781,250 and the Company agreed to pay $20,000 t
- $20,000 — $781,250 and the Company agreed to pay $20,000 to the Investor to cover the Investor's
- $2,500,000 — rchase price received by the Company of $2,500,000. The Note bears interest at ten perce
- $250,000 — to redeem any amount of the Note up to $250,000 (such amount, the "Monthly Redemption A
Filing Documents
- form8-k.htm (8-K) — 44KB
- ex10-1.htm (EX-10.1) — 130KB
- ex10-2.htm (EX-10.2) — 46KB
- 0001493152-25-024156.txt ( ) — 424KB
- aim-20251118.xsd (EX-101.SCH) — 3KB
- aim-20251118_lab.xml (EX-101.LAB) — 33KB
- aim-20251118_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AIM IMMUNOTECH INC. November 19, 2025 By: /s/ Thomas K. Equels Thomas K. Equels, CEO 3